<DOC>
	<DOCNO>NCT01111448</DOCNO>
	<brief_summary>The goal Pilot-study evaluate response unselected MDS patient temsirolimus drug approve treatment renal cell cancer . It plan give temsirolimus weekly dose 25 mg intravenous infusion maximum duration 12 month . Regular bone marrow biopsy plan control MDS response .</brief_summary>
	<brief_title>Temsirolimus Myelodysplastic Syndrome ( MDS )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Age &gt; 18 year time signing informed consent form ; Patients able understand consequence participate trial disorder circumstance ( i.e . ward imprison ) keep give write informed consent ; cytologically histologically establish diagnosis de novo therapyrelated MDS accord FABclassification , either previously treat untreated , presenting : Group I ( lowrisk ) : Low INT1 risk feature accord IPSS require least 4 unit red blood cell within last 8 week prior screen visit present neutropenia ( &lt; 1 Gpt/l neutrophil ) Group II ( highrisk ) : INT2 HIGHrisk IPSS refractory intolerant 5Azacytidine . CMML patient dysplastic phenotype ( WBC &lt; 13 Gpt/l ) may include arm accord IPSS . CMML patient show proliferative phenotype ( WBC &gt; =13 Gpt/l ) include high risk arm ; eligible immediate allogeneic HSCT conventional chemotherapy ; previous MDS specific therapy ( except supportive approach like transfusion antibiotic ) must discontinue least 4 week prior study enrollment ; ECOG performance status &lt; = 3 study entry ; laboratory test result within range : Serum creatinine &lt; = 177 Âµmo/l ( &lt; = 2.0 mg/dL ) ; total bilirubin &lt; = 3 x ULN ; AST ( SGOT ) ALT ( SGPT ) &lt; = 3 x ULN ; total fasting cholesterol &lt; = 9.1 mmol/l ( 350 mg/dl ) ; fast triglyceride level &lt; = 4.5 mmol/l ( 400 mg/dl ) ; platelet &gt; 25 Gpt/l without transfusion support patient LOW INT1 Risk accord IPSS ; sign informed consent . For Patients LOW INT1Risk accord IPSS : Thrombocytopenia 25 Gpt/l ( INT2 HIGHIPSS patient may include irrespective platelet count ) ; know hypersensitivity temsirolimus , sirolimus component infusion solution ( dlalphatocopherol , propylene glycol , anhydrous citric acid , polysorbate 80 , polyethylene glycol 400 , dehydrate alcohol ) ; know hypersensitivity macrolid antibiotic ( structural similarity class antibiotic study medication ) ; condition , include presence laboratory abnormality , place subject unacceptable risk he/she participate study confounds ability interpret data study ; know positive HIV uncontrolled infection ; presence malignancy complete remission least 3 year ( previous chemotherapy malignancy exclusion criterion ) ; necessity therapeutic anticoagulation ( exclude low dose ASS ) ; participation clinical trial within last 4 week ; pregnant breast feeding female ( lactate female must agree breast feed study ) ; female childbearing potential ( FCBP ) except fulfil least one follow criterion : postmenopausal ( 12 month natural amenorrhea 6 month amenorrhea serum FSH &gt; 40 U/ml ) ; postsurgery ( 6 week bilateral ovarectomy without hysterectomy ) ; regular correct use contraceptive PEARL Index &lt; 1 % ( e.g . implant , depot formulation hormone , oral contraceptive , intra uterine device IUD ) ; sexual abstinence ; partner , vasectomy ( confirm two negative analysis semen ) ; male patient , agree use latex condom sexual contact female childbearing potential participate study least 3 month follow discontinuation study even undergone successful vasectomy ; patient history chronic drug abuse another illness allow patient assess nature and/or possible consequence study ; patient likely follow trial protocol ( lack willingness cooperate ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Myelodysplastic Syndromes IPSS subgroup</keyword>
</DOC>